• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

COVID-19 患者住院时的细菌合并感染。

Bacterial co-infection at hospital admission in patients with COVID-19.

机构信息

Infectious Diseases Department, Hospital Clinic of Barcelona-IDIBAPS, Universitat de Barcelona, Barcelona, Spain.

Infectious Diseases Department, Hospital Clinic of Barcelona-IDIBAPS, Universitat de Barcelona, Barcelona, Spain.

出版信息

Int J Infect Dis. 2022 May;118:197-202. doi: 10.1016/j.ijid.2022.03.003. Epub 2022 Mar 5.

DOI:10.1016/j.ijid.2022.03.003
PMID:35257905
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8896874/
Abstract

OBJECTIVES

We described the current incidence and risk factors of bacterial co-infection in hospitalized patients with COVID-19.

METHODS

Observational cohort study was performed at the Hospital Clinic of Barcelona (February 2020-February 2021). All patients with COVID-19 who were admitted for >48 hours with microbiological sample collection and procalcitonin (PCT) determination within the first 48 hours were included.

RESULTS

A total of 1125 consecutive adults met inclusion criteria. Co-infections were microbiologically documented in 102 (9.1%) patients. Most frequent microorganisms were Streptococcus pneumoniae (79%), Staphylococcus aureus (6.8%), and Haemophilus influenzae (6.8%). Test positivity was 1% (8/803) for blood cultures, 10.1% (79/780) for pneumococcal urinary antigen test, and 11.4% (15/132) for sputum culture. Patients with PCT higher than 0.2, 0.5, 1, and 2 ng/mL had significantly more co-infections than those with lower levels (p=0.017, p=0.031, p<0.001, and p<0.001, respectively). In multivariate analysis, oxygen saturation ≤94% (OR 2.47, CI 1.57-3.86), ferritin levels <338 ng/mL (OR 2.63, CI 1.69-4.07), and PCT higher than 0.2 ng/mL (OR 1.74, CI 1.11-2.72) were independent risk factors for co-infection at hospital admission owing to COVID-19.

CONCLUSIONS

Bacterial co-infection in patients hospitalized for COVID-19 is relatively common. However, clinicians could spare antibiotics in patients with PCT values <0.2, especially with high ferritin values and oxygen saturation >94%.

摘要

目的

我们描述了住院 COVID-19 患者中细菌合并感染的当前发生率和危险因素。

方法

在巴塞罗那临床医院进行了观察性队列研究(2020 年 2 月至 2021 年 2 月)。所有因 COVID-19 住院>48 小时且在最初 48 小时内采集了微生物样本并测定降钙素原(PCT)的患者均符合纳入标准。

结果

共纳入 1125 例连续的成年人。102 例(9.1%)患者有合并感染的微生物学证据。最常见的微生物是肺炎链球菌(79%)、金黄色葡萄球菌(6.8%)和流感嗜血杆菌(6.8%)。血培养阳性率为 1%(8/803),肺炎球菌尿抗原检测阳性率为 10.1%(79/780),痰培养阳性率为 11.4%(15/132)。PCT 高于 0.2、0.5、1 和 2ng/mL 的患者合并感染的比例显著高于 PCT 较低水平的患者(p=0.017,p=0.031,p<0.001,p<0.001)。多变量分析显示,血氧饱和度≤94%(OR 2.47,95%CI 1.57-3.86)、铁蛋白水平<338ng/mL(OR 2.63,95%CI 1.69-4.07)和 PCT 高于 0.2ng/mL(OR 1.74,95%CI 1.11-2.72)是 COVID-19 住院患者合并感染的独立危险因素。

结论

COVID-19 住院患者中细菌合并感染较为常见。然而,对于 PCT 值<0.2 的患者,特别是铁蛋白值高和血氧饱和度>94%的患者,可避免使用抗生素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17ec/8896874/7558a14f921f/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17ec/8896874/7558a14f921f/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17ec/8896874/7558a14f921f/gr1_lrg.jpg

相似文献

1
Bacterial co-infection at hospital admission in patients with COVID-19.COVID-19 患者住院时的细菌合并感染。
Int J Infect Dis. 2022 May;118:197-202. doi: 10.1016/j.ijid.2022.03.003. Epub 2022 Mar 5.
2
Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study.COVID-19 住院患者合并感染和再感染的发生率:一项回顾性队列研究。
Clin Microbiol Infect. 2021 Jan;27(1):83-88. doi: 10.1016/j.cmi.2020.07.041. Epub 2020 Jul 31.
3
Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting.COVID-19 住院患者的细菌和真菌感染:英国二级保健机构中的回顾性队列研究。
Clin Microbiol Infect. 2020 Oct;26(10):1395-1399. doi: 10.1016/j.cmi.2020.06.025. Epub 2020 Jun 27.
4
Few bacterial co-infections but frequent empiric antibiotic use in the early phase of hospitalized patients with COVID-19: results from a multicentre retrospective cohort study in The Netherlands.在荷兰的一项多中心回顾性队列研究中,COVID-19 住院患者早期的细菌合并感染较少,但经验性抗生素使用频繁。
Infect Dis (Lond). 2021 Feb;53(2):102-110. doi: 10.1080/23744235.2020.1839672. Epub 2020 Oct 24.
5
Searching for a role of procalcitonin determination in COVID-19: a study on a selected cohort of hospitalized patients.探讨降钙素原测定在 COVID-19 中的作用:一项针对住院患者的选定队列研究。
Clin Chem Lab Med. 2020 Nov 19;59(2):433-440. doi: 10.1515/cclm-2020-1361.
6
Pulmonary bacterial infections in adult patients hospitalized for COVID-19 in standard wards.成人 COVID-19 标准病房住院患者的肺部细菌性感染。
Infect Dis Now. 2022 Jun;52(4):208-213. doi: 10.1016/j.idnow.2021.12.001. Epub 2021 Dec 9.
7
Diagnostic yield of bacteriological tests and predictors of severe outcome in adult patients with COVID-19 presenting to the emergency department.在因 COVID-19 而到急诊科就诊的成年患者中,细菌学检测的诊断效果及其导致重症的预测因子。
Emerg Med J. 2021 Sep;38(9):685-691. doi: 10.1136/emermed-2020-211027. Epub 2021 Jul 21.
8
Bacterial and Fungal Coinfection in Critically Ill COVID-19 Cases and Predictive Role of Procalcitonin During the First Wave at an Academic Health Center.在学术医疗中心第一波疫情中,危重症 COVID-19 病例中的细菌和真菌感染及降钙素原的预测作用。
J Epidemiol Glob Health. 2022 Jun;12(2):188-195. doi: 10.1007/s44197-022-00038-4. Epub 2022 Apr 9.
9
High procalcitonin levels associated with increased intensive care unit admission and mortality in patients with a COVID-19 infection in the emergency department.血清降钙素原水平与急诊科 COVID-19 感染患者入住重症监护病房和死亡风险增加相关。
BMC Infect Dis. 2022 Feb 21;22(1):165. doi: 10.1186/s12879-022-07144-5.
10
Clinical and etiological analysis of co-infections and secondary infections in COVID-19 patients: An observational study.新型冠状病毒肺炎患者合并感染和继发感染的临床和病因学分析:一项观察性研究。
Clin Respir J. 2021 Jul;15(7):815-825. doi: 10.1111/crj.13369. Epub 2021 Apr 19.

引用本文的文献

1
Serum metabolomic characteristics of COVID-19 patients co-infection with echovirus.新冠病毒感染合并埃可病毒感染患者的血清代谢组学特征
Virulence. 2025 Dec;16(1):2497907. doi: 10.1080/21505594.2025.2497907. Epub 2025 May 1.
2
Targeting USP22 to promote K63-linked ubiquitination and degradation of SARS-CoV-2 nucleocapsid protein.靶向USP22以促进SARS-CoV-2核衣壳蛋白的K63连接的泛素化和降解。
J Virol. 2025 May 20;99(5):e0223424. doi: 10.1128/jvi.02234-24. Epub 2025 Apr 4.
3
Blood Inflammatory Markers and Cytokines in COVID-19 Patients With Bacterial Coinfections.

本文引用的文献

1
Is procalcitonin a reliable marker of bacterial community-acquired pneumonia in adults admitted to the emergency department during SARS-CoV-2 pandemic?在2019冠状病毒病大流行期间,降钙素原是否是急诊科收治的成年患者社区获得性细菌性肺炎的可靠标志物?
Eur J Emerg Med. 2021 Aug 1;28(4):312-314. doi: 10.1097/MEJ.0000000000000796.
2
C-reactive protein and procalcitonin for antimicrobial stewardship in COVID-19.C 反应蛋白和降钙素原在 COVID-19 中的抗菌药物管理作用。
Infection. 2021 Oct;49(5):935-943. doi: 10.1007/s15010-021-01615-8. Epub 2021 May 22.
3
Elevated procalcitonin concentrations in severe Covid-19 may not reflect bacterial co-infection.
新冠病毒合并细菌感染患者的血液炎症标志物和细胞因子
Immun Inflamm Dis. 2024 Dec;12(12):e70105. doi: 10.1002/iid3.70105.
4
Mortality in hospitalized SARS-CoV-2 patients with contemporaneous bacterial and fungal infections.同时合并细菌和真菌感染的住院新冠病毒患者的死亡率
Antimicrob Steward Healthc Epidemiol. 2024 Sep 23;4(1):e142. doi: 10.1017/ash.2024.424. eCollection 2024.
5
Are C-reactive protein and procalcitonin safe and useful for antimicrobial stewardship purposes in patients with COVID-19? A scoping review.C反应蛋白和降钙素原对COVID-19患者进行抗菌药物管理而言安全且有用吗?一项范围综述。
Antimicrob Steward Healthc Epidemiol. 2024 Sep 12;4(1):e129. doi: 10.1017/ash.2024.372. eCollection 2024.
6
Cyclic-di-GMP induces inflammation and acute lung injury through direct binding to MD2.环二鸟苷酸通过直接结合 MD2 诱导炎症和急性肺损伤。
Clin Transl Med. 2024 Aug;14(8):e1744. doi: 10.1002/ctm2.1744.
7
The Impact of Early Antibiotic Use on Clinical Outcomes of Patients Hospitalized with COVID-19: A Propensity Score-Matched Analysis.早期使用抗生素对COVID-19住院患者临床结局的影响:一项倾向评分匹配分析。
Infect Drug Resist. 2024 Aug 9;17:3425-3438. doi: 10.2147/IDR.S470957. eCollection 2024.
8
Timing and prediction of secondary bacteremia in patients with COVID-19: A retrospective cohort study.2019冠状病毒病患者继发性菌血症的时间及预测:一项回顾性队列研究。
J Gen Fam Med. 2024 Apr 30;25(4):206-213. doi: 10.1002/jgf2.697. eCollection 2024 Jul.
9
Metaproteomics for Coinfections in the Upper Respiratory Tract: The Case of COVID-19.用于上呼吸道合并感染的宏蛋白质组学:以COVID-19为例
Methods Mol Biol. 2024;2820:165-185. doi: 10.1007/978-1-0716-3910-8_15.
10
Co-Infection of SARS-CoV-2 and : A Systematic Review and Meta-Analysis.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)合并感染:一项系统评价与荟萃分析 。 你提供的原文中“and”后面内容缺失,我按照常规情况补充了“其他病原体”之类的通用表述进行翻译,你可根据实际情况调整。
Diagnostics (Basel). 2024 May 30;14(11):1149. doi: 10.3390/diagnostics14111149.
严重 COVID-19 患者降钙素原浓度升高可能不反映细菌合并感染。
Ann Clin Biochem. 2021 Sep;58(5):520-527. doi: 10.1177/00045632211022380. Epub 2021 Jun 18.
4
Trends in mortality of hospitalised COVID-19 patients: A single centre observational cohort study from Spain.住院新冠肺炎患者的死亡率趋势:一项来自西班牙的单中心观察性队列研究。
Lancet Reg Health Eur. 2021 Apr;3:100041. doi: 10.1016/j.lanepe.2021.100041. Epub 2021 Jan 24.
5
Limited Utility of Procalcitonin in Identifying Community-Associated Bacterial Infections in Patients Presenting with Coronavirus Disease 2019.降钙素原在识别因 2019 年冠状病毒病就诊的患者中的社区获得性细菌感染的作用有限。
Antimicrob Agents Chemother. 2021 Mar 18;65(4). doi: 10.1128/AAC.02167-20.
6
Evaluation of procalcitonin as a contribution to antimicrobial stewardship in SARS-CoV-2 infection: a retrospective cohort study.降钙素原评估在 SARS-CoV-2 感染中的抗菌药物管理贡献:一项回顾性队列研究。
J Hosp Infect. 2021 Apr;110:103-107. doi: 10.1016/j.jhin.2021.01.006. Epub 2021 Jan 20.
7
Dynamics of Pneumococcal Carriage in Adults: A New Look at an Old Paradigm.成人肺炎链球菌携带动力学:旧观念的新视角。
J Infect Dis. 2021 May 20;223(9):1590-1600. doi: 10.1093/infdis/jiaa558.
8
Low rate of bacterial co-infection in patients with COVID-19.新冠病毒病患者细菌合并感染率低。
Lancet Microbe. 2020 Jun;1(2):e62. doi: 10.1016/S2666-5247(20)30036-7. Epub 2020 Jun 8.
9
Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study.COVID-19 住院患者合并感染和再感染的发生率:一项回顾性队列研究。
Clin Microbiol Infect. 2021 Jan;27(1):83-88. doi: 10.1016/j.cmi.2020.07.041. Epub 2020 Jul 31.
10
Personalized Therapy Approach for Hospitalized Patients with Coronavirus Disease 2019.个体化治疗方案在 2019 冠状病毒病住院患者中的应用
Clin Infect Dis. 2022 Jan 7;74(1):127-132. doi: 10.1093/cid/ciaa964.